Keep pulling the thread on Marc Tessier Lavigne.
Xaira, referred to as Zera, was launched with $1 billion in funding to focus on AI drug discovery.
One month prior to the summit, Xaira published its first AI model, which was trained on more causal biological data than the entire world had generated to date.
Xaira's strategy is to use AI to pursue difficult drug targets, described as 'high-hanging fruit', that are inaccessible with conventional drug discovery methods.
Xaira has been deploying its capital over the last few years to generate massive amounts of data for creating foundational models of biology.
For a promising drug target addressable by conventional methods, there will typically be 20 competing companies, 10 of which are based in China.
Marc Tessier Lavigne believes that combining advanced diagnostics with AI models, such as those from Xaira, will increase the success rate of clinical trials.